山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (9): 42-46.doi: 10.6040/j.issn.1671-7554.0.2022.0880
林芸,谢燕秋
LIN Yun, XIE Yanqiu
摘要： 乳腺癌是女性最常见的恶性肿瘤。随着乳腺癌筛查的推广以及综合治疗的开展,乳腺癌患者的无瘤生存率和总生存率得到大大提高,年轻乳腺癌患者的生育需求受到越来越多的关注,生育力保存显得尤为重要。论文从乳腺癌治疗对卵巢功能的影响、生育力保存的方法以及乳腺癌患者进行辅助生殖相关研究进展三个方面进行阐述,为临床上乳腺癌患者进行生育力保存提供参考。
中图分类号:
| [1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [2] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13. LIU Zongchao, LI Zhexuan, ZHANG Yang, et al. Interpretation on the report of Global Cancer Statistics[J]. Journal of Multidisciplinary Cancer Management(Electronic Version), 2021, 7(2): 1-13. [3] Li J, Zhang BN, Fan JH, et al. A nation-wide multicenter 10-year(1999-2008)retrospective clinical epidemiological study of female breast cancer in China[J]. BMC Cancer, 2011, 11: 364. doi: 10.1186/1471-2407-11-364. [4] Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO Clinical Practice Guideline update[J]. J Clin Oncol, 2018, 36(19): 1994-2001. [5] Liem GS, Mo FK, Pang E, et al. Chemotherapy-related amenorrhea and menopause in young Chinese breast cancer patients: analysis on incidence, risk factors and serum hormone profiles[J]. PLoS One, 2015, 10(10): e0140842. [6] Meirow D, Biederman H, Anderson RA, et al. Toxicity of chemotherapy and radiation on female reproduction[J]. Clin Obstet Gynecol, 2010, 53(4): 727-739. [7] Overbeek A, van den Berg MH, van Leeuwen FE, et al. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: a systematic review[J]. Cancer Treat Rev, 2017, 53: 10-24. doi: 10.1016/j.ctrv.2016.11.006. [8] Minisini AM, Menis J, Valent F, et al. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era[J]. Anticancer Drugs, 2009, 20(6): 503-507. [9] Tiong V, Rozita AM, Taib NA, et al. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer[J]. World J Surg, 2014, 38(9): 2288-2296. [10] Shin JJ, Choi YM, Jun JK, et al. Amenorrhea and menopause in patients with breast cancer after chemotherapy[J]. J Breast Cancer, 2019, 22(4): 624-634. [11] Furlanetto J, Marmé F, Seiler S, et al. Chemotherapy-induced ovarian failure in young women with early breast cancer: prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials[J]. Eur J Cancer, 2021, 152: 193-203. doi: 10.1016/j.ejca.2021.04.038. [12] Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies[J]. Eur J Cancer, 2017, 71: 34-42. doi: 10.1016/j.ejca.2016.10.030. [13] Ganz PA, Cecchini RS, Fehrenbacher L, et al. NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab[J]. NPJ Breast Cancer, 2021, 7(1): 55-61. [14] Cosgrove CM, Salani R. Ovarian effects of radiation and cytotoxic chemotherapy damage[J]. Best Pract Res Clin Obstet Gynaecol, 2019, 55: 37-48. doi: 10.1016/j.bpobgyn.2018.07.008. [15] Wallace WHB, Thomson AB, Saran F, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries[J]. Int J Radiat Oncol Biol Phys, 2005, 62(3): 738-744. [16] Mazonakis M, Varveris H, Damilakis J, et al. Radiation dose to conceptus resulting from tangential breast irradiation[J]. Int J Radiat Oncol Biol Phys, 2003 55(2): 386-391. [17] 中国年轻乳腺癌诊疗与生育管理专家共识专家委员会. 年轻乳腺癌诊疗与生育管理专家共识[J]. 中华肿瘤杂志, 2019, 41(7): 486-495. [18] Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer[J]. Cancer, 2010, 116(4): 791-798. [19] Ruddy KJ, Guo H, Barry W, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab(APT trial)[J]. Breast Cancer Res Treat, 2015, 151(3): 589-596. [20] Poorvu PD, Hu J, Zheng Y, et al. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer[J]. NPJ Breast Cancer, 2021, 7(1): 99-105. [21] Huser M, Smardova L, Janku P, et al. Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analogues[J]. J Assist Reprod Genet, 2015, 32(8): 1187-1193. [22] Horicks F, Van Den Steen G, Houben S, et al. Folliculogenesis is not fully inhibited during GnRH analogues treatment in mice challenging their efficiency to preserve the ovarian reserve during chemotherapy in this model[J]. PLoS One, 2015, 10(9): e0137164. [23] Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and Meta-analysis[J]. JAMA Oncol, 2016, 2(1): 65-73. [24] Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and Meta-analysis of individual patient-level data[J]. J Clin Oncol, 2018, 36(19):1981-1990. [25] Moore HCF, Unger JM, Phillips KA, et al. Final analysis of the prevention of early menopause study(POEMS)/SWOG Intergroup S0230[J]. J Natl Cancer Inst, 2019, 111(2): 210-213. [26] Zong X, Yu Y, Yang H, et al. Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial[J]. JAMA Oncol, 2022, 8(2): 252-258. [27] Preservation TEGGoFF. ESHRE FFP Guideline: female fertility preservation[J]. Hum Reprod Open, 2020: 1-17. [28] 中华医学会生殖医学分会. 生育力保存中国专家共识[J]. 生殖医学杂志, 2021, 30(9): 1129-1134. Chinese Society of Reproductive Medicine. Chinese expert consensus on fertility preservation[J]. Journal of Reproductive Medicine, 2021, 30(9): 1129-1134. [29] 中国妇幼保健协会生育力保存专业委员会. 女性生育力保存临床实践中国专家共识[J]. 中华生殖与避孕杂志, 2021, 41(5): 383-391. [30] Dolmans MM, Luyckx V, Donnez J, et al. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue[J]. Fertil Steril, 2013, 99(6): 1514-1522. [31] Rodgers RJ, Reid GD, Koch J, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review[J]. Hum Reprod, 2017, 32(5): 1033-1045. [32] Letourneau JM, Wald K, Sinha N, et al. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation[J]. Cancer, 2020, 126(3): 487-495. [33] Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy[J]. J Clin Endocrinol Metab, 2006, 91(10): 3885-3890. [34] Turan V, Bedoschi G, Emirdar V, et al. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes[J]. Reprod Sci, 2018, 25(1): 26-32. [35] Marklund A, Eloranta S, Wikander I, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer—a prospective nationwide Swedish multicenter study[J]. Hum Reprod, 2020, 35(4): 929-938. [36] Oktay K, Buyuk E, Libertella N, et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation[J]. J Clin Oncol, 2005, 23(19): 4347-4353. [37] Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation[J]. Reprod Biomed Online, 2010, 20(6): 783-788. [38] Goldrat O, Van Den Steen G, Gonzalez-Merino E, et al. Letrozole-associated controlled ovarian hyperstimulation in breast cancer patients versus conventional controlled ovarian hyperstimulation in infertile patients: assessment of oocyte quality related biomarkers[J]. Reprod Biol Endocrinol, 2019, 17(1): 3-11. [39] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers[J]. JAMA, 2017, 317(23): 2402-2416. [40] Turan V, Demeestere I, Lambertini M, et al. Association of germline BRCA pathogenic variants with diminished ovarian reserve: a Meta-analysis of individual patient-level data[J]. J Clin Oncol, 2021, 39(18): 2016-2024. [41] Rodriguez-Wallberg KA, Oktay K. Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer[J]. Oncologist, 2012, 17(11): 1409-1417. [42] Derks-Smeets IA, de Die-Smulders CE, Mackens S, et al. Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors[J]. Breast Cancer Res Treat, 2014, 145(3): 673-681. [43] Hartnett KP, Mertens AC, Kramer MR, et al. Pregnancy after cancer: does timing of conception affect infant health?[J]. Cancer, 2018, 124(22): 4401-4407. [44] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040. |
| [1] | 郝桂敏,罗卓野,王奕卓. 生育力保存的伦理问题及思考[J]. 山东大学学报 (医学版), 2022, 60(9): 47-52. |
| [2] | 阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30. |
| [3] | 石玉华,潘烨,谢燕秋. 胚胎冷冻保存技术及进展[J]. 山东大学学报 (医学版), 2022, 60(9): 12-18. |
| [4] | 杨其峰,张宁. 精准医疗时代的乳腺癌前哨淋巴结活检[J]. 山东大学学报 (医学版), 2022, 60(8): 1-5. |
| [5] | 贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43. |
| [6] | 赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24-29. |
| [7] | 封海岗,刘国文,曹洪. 干扰MAD2L1基因表达对乳腺癌细胞凋亡的影响及机制[J]. 山东大学学报 (医学版), 2022, 60(10): 9-16. |
| [8] | 初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139. |
| [9] | 王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118. |
| [10] | 李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84. |
| [11] | 朱序理,周亮,王跃,孙庆云,曹明雅,杜元杰,曹金凤,赵志明,郝桂敏. 不同精子来源质量冷冻方式与妊娠结局的关联性分析[J]. 山东大学学报 (医学版), 2021, 59(6): 86-93. |
| [12] | 孔雪,李娟,段伟丽,史爽,李培龙,杜鲁涛,毛海婷,王传新. 长链非编码RNA AC012073.1对乳腺癌细胞迁移侵袭的影响及临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 70-78. |
| [13] | 郭田,付依林,高聆,宋勇峰,付国斌,耿冲,王潍博. 142例女性乳腺癌患者临床特征与甲状腺激素水平的关联分析[J]. 山东大学学报 (医学版), 2020, 58(6): 53-59. |
| [14] | 杨雪梅,李娟,王一凡,李培龙,王允山,杜鲁涛,王传新. 3-lncRNAs预后模型在HER2阳性乳腺癌预后评价中的意义[J]. 山东大学学报 (医学版), 2020, 58(5): 69-76. |
| [15] | 高奎,万广宁,宋晓鹏,信波. 吡咯替尼治疗曲妥珠耐药HER2阳性乳腺癌1例[J]. 山东大学学报 (医学版), 2020, 58(12): 117-120. |
|
